Skip to main content
Top
Published in: Current Gastroenterology Reports 2/2010

01-04-2010

Sphincter of Oddi Dysfunction

Author: John Baillie

Published in: Current Gastroenterology Reports | Issue 2/2010

Login to get access

Abstract

Sphincter of Oddi dysfunction (SOD) is a poorly-understood disorder, typically presenting as postcholecystectomy, “biliary-type,” right-sided abdominal and/or chest wall pain. Most patients referred to specialist clinics for work-up of presumed SOD do not, in fact, have anything wrong with their bile ducts or biliary sphincter mechanisms. A careful history and focused physical examination will often identify the true source of the pain syndrome, ranging from chest wall costochondritis and nerve injury at surgical trochar sites, to gastroparesis and visceral hypersensitivity (“irritable bowel”). The Rome III classification of functional gallbladder and biliary disorders defines SOD as episodic (not daily) pain lasting more than 30 min, which is disruptive of normal activities and not associated with bowel upset. It is not relieved by gastric acid suppression or antispasmodics. Other causes of abdominal pain must be excluded. Standard work-up includes endoscopic retrograde cholangiopancreatography (ERCP) with biliary manometry, which risks post-ERCP pancreatitis, especially in young women with normal bile ducts and liver serology. Noninvasive tests for SOD, such as timed (“gated”) cholecystokinin (CCK)-stimulated hepatobiliary iminodiacetic acid (HIDA) scans and secretin-stimulated magnetic resonance cholangiopancreatography, are imperfect and still evolving. Although many doubt the very existence of SOD, a multidisciplinary approach to the management of pre- and postcholecystectomy abdominal pain syndromes is long overdue.
Literature
1.
go back to reference Geenen JE, Hogan WJ, Dodds WJ, et al.: The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med 1989, 320:82–87.PubMedCrossRef Geenen JE, Hogan WJ, Dodds WJ, et al.: The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med 1989, 320:82–87.PubMedCrossRef
2.
go back to reference Toouli J: Sphincter of Oddi: function, dysfunction, and its management. J Gastroenterol Hepatol 2009, 24(Suppl 3):S57–S62.CrossRefPubMed Toouli J: Sphincter of Oddi: function, dysfunction, and its management. J Gastroenterol Hepatol 2009, 24(Suppl 3):S57–S62.CrossRefPubMed
3.
go back to reference Behar J, Corazziari E, Guelrud M, et al.: Functional gallbladder and sphincter of Oddi disorders. Gastroenterology 2006, 130:1498–1509.CrossRefPubMed Behar J, Corazziari E, Guelrud M, et al.: Functional gallbladder and sphincter of Oddi disorders. Gastroenterology 2006, 130:1498–1509.CrossRefPubMed
5.
go back to reference Ruffolo TA, Sherman S, Lehman, et al.: Gallbladder ejection fraction and its relationship to sphincter of Oddi dysfunction. Dig Dis Sci 1994, 39:289–292. Ruffolo TA, Sherman S, Lehman, et al.: Gallbladder ejection fraction and its relationship to sphincter of Oddi dysfunction. Dig Dis Sci 1994, 39:289–292.
6.
go back to reference Choudhry U, Ruffolo T, Jamidar P, et al.: Sphincter of Oddi dysfunction in patients with intact gallbladder: therapeutic response to endoscopic sphincterotomy. Gastrointest Endosc 1993; 39:492–495.CrossRefPubMed Choudhry U, Ruffolo T, Jamidar P, et al.: Sphincter of Oddi dysfunction in patients with intact gallbladder: therapeutic response to endoscopic sphincterotomy. Gastrointest Endosc 1993; 39:492–495.CrossRefPubMed
7.
go back to reference Freeman ML, Guda NM: Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004, 59:845–864.CrossRefPubMed Freeman ML, Guda NM: Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004, 59:845–864.CrossRefPubMed
8.
go back to reference Freeman ML: Post-ERCP pancreatitis: patient and technique-related risk factors. JOP 2002, 3:169–176.PubMed Freeman ML: Post-ERCP pancreatitis: patient and technique-related risk factors. JOP 2002, 3:169–176.PubMed
9.
go back to reference Saad AM, Fogel EL, McHenry L, et al.: Pancreatic duct stent placement prevents post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction but normal manometry results. Gastrointest Endosc 2008, 67:255–261.CrossRefPubMed Saad AM, Fogel EL, McHenry L, et al.: Pancreatic duct stent placement prevents post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction but normal manometry results. Gastrointest Endosc 2008, 67:255–261.CrossRefPubMed
10.
go back to reference • Freeman ML: Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007, 5:1354–1365. This article describes the role of pancreatic stents in the prevention of post-ERCP pancreatitis, as discussed by the pioneer in the field. • Freeman ML: Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007, 5:1354–1365. This article describes the role of pancreatic stents in the prevention of post-ERCP pancreatitis, as discussed by the pioneer in the field.
11.
go back to reference Senol A, Saritas U, Demirkan H: Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol 2009, 15:3999–4004.CrossRefPubMed Senol A, Saritas U, Demirkan H: Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol 2009, 15:3999–4004.CrossRefPubMed
12.
go back to reference • Elmunzer BJ, Waljee AK, Elta GH, et al.: A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008, 57:1262–1267. This article presents a meta-analysis of four prospective studies appearing to show that NSAIDs may significantly reduce the risk of post-ERCP pancreatitis. • Elmunzer BJ, Waljee AK, Elta GH, et al.: A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008, 57:1262–1267. This article presents a meta-analysis of four prospective studies appearing to show that NSAIDs may significantly reduce the risk of post-ERCP pancreatitis.
13.
go back to reference Staritz M, Poralla T, Dormeyer HH, et al.: Endoscopic removal of common bile duct stones through the intact papilla after medical sphincter dilation. Gastroenterology 1985, 88:1807–1811.PubMed Staritz M, Poralla T, Dormeyer HH, et al.: Endoscopic removal of common bile duct stones through the intact papilla after medical sphincter dilation. Gastroenterology 1985, 88:1807–1811.PubMed
14.
go back to reference Madácsy L, Kurucsai G, Fejes R, et al, Prophylactic pancreas stenting followed by needle-knife fistulotomy in patients with sphincter of Oddi dysfunction and difficult cannulation: new method to prevent post-ERCP pancreatitis. Dig Endosc 2009, 21:8–13.CrossRefPubMed Madácsy L, Kurucsai G, Fejes R, et al, Prophylactic pancreas stenting followed by needle-knife fistulotomy in patients with sphincter of Oddi dysfunction and difficult cannulation: new method to prevent post-ERCP pancreatitis. Dig Endosc 2009, 21:8–13.CrossRefPubMed
15.
go back to reference Freeman ML: Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007, 5:1354–1365.CrossRefPubMed Freeman ML: Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007, 5:1354–1365.CrossRefPubMed
16.
go back to reference Cheon YK, Cho YD, Moon JH, et al.: Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009, 69:1111–1116.CrossRefPubMed Cheon YK, Cho YD, Moon JH, et al.: Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009, 69:1111–1116.CrossRefPubMed
17.
go back to reference Affronti J: Levitra for sphincter of Oddi dysfunction? Are you kidding? Gastrointest Endosc 2009, 69:1117–1119.CrossRefPubMed Affronti J: Levitra for sphincter of Oddi dysfunction? Are you kidding? Gastrointest Endosc 2009, 69:1117–1119.CrossRefPubMed
18.
go back to reference Khashab MA, Watkins JL, McHenry Jr L, et al.: Frequency of sphincter of Oddi dysfunction in patients with previously normal sphincter of Oddi manometry studies. Endoscopy 2009 (Epub ahead of print). Khashab MA, Watkins JL, McHenry Jr L, et al.: Frequency of sphincter of Oddi dysfunction in patients with previously normal sphincter of Oddi manometry studies. Endoscopy 2009 (Epub ahead of print).
19.
go back to reference Draganov PV, Kowalczyk L, Forsmark CE: Prospective trial comparing solid-state catheter and water-perfusion triple-lumen catheter for sphincter of Oddi manometry done at the time of ERCP. Gastrointest Endosc 2009, 70:92–95.CrossRefPubMed Draganov PV, Kowalczyk L, Forsmark CE: Prospective trial comparing solid-state catheter and water-perfusion triple-lumen catheter for sphincter of Oddi manometry done at the time of ERCP. Gastrointest Endosc 2009, 70:92–95.CrossRefPubMed
20.
go back to reference Aisen AM, Sherman S, Jennings SG, et al.: Comparison of secretin-stimulated magnetic resonance pancreatography and manometry results in patients with suspected sphincter of Oddi dysfunction. Acad Radiol 2008, 15:601–609.CrossRefPubMed Aisen AM, Sherman S, Jennings SG, et al.: Comparison of secretin-stimulated magnetic resonance pancreatography and manometry results in patients with suspected sphincter of Oddi dysfunction. Acad Radiol 2008, 15:601–609.CrossRefPubMed
21.
go back to reference Baillie J, Kimberly J: Prospective comparison of secretin-stimulated MRCP with manometry in the diagnosis of sphincter of Oddi dysfunction types II and III. Gut 2007, 56:742–744.CrossRefPubMed Baillie J, Kimberly J: Prospective comparison of secretin-stimulated MRCP with manometry in the diagnosis of sphincter of Oddi dysfunction types II and III. Gut 2007, 56:742–744.CrossRefPubMed
22.
go back to reference Elmi F, Silverman WB: biliary sphincter of Oddi dysfunction type I versus occult biliary microlithiasis in post-cholecystectomy patients: are they both part of the same clinical entity? Dig Dis Sci 2009 (Epub ahead of print). Elmi F, Silverman WB: biliary sphincter of Oddi dysfunction type I versus occult biliary microlithiasis in post-cholecystectomy patients: are they both part of the same clinical entity? Dig Dis Sci 2009 (Epub ahead of print).
24.
go back to reference Cohen S, Bacon B, Berlin JA, et al.: National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14–16, 2002. Gastrointest Endosc 2002, 56:803–809.CrossRefPubMed Cohen S, Bacon B, Berlin JA, et al.: National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14–16, 2002. Gastrointest Endosc 2002, 56:803–809.CrossRefPubMed
Metadata
Title
Sphincter of Oddi Dysfunction
Author
John Baillie
Publication date
01-04-2010
Publisher
Current Science Inc.
Published in
Current Gastroenterology Reports / Issue 2/2010
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-010-0096-1

Other articles of this Issue 2/2010

Current Gastroenterology Reports 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.